An estimated 40% of the global adult population have high blood pressure, or hypertension, which puts people at risk of cardiovascular disease and other dangerous health conditions.
AstraZeneca scores its second paediatric approval for Soliris in Japan – Pharmaceutical Technology
Soliris has previously been approved for use in paediatric and adult populations with paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in the
August 25, 2023